Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma
Thyroid2013Vol. 24(2), pp. 232–240
Citations Over TimeTop 10% of 2013 papers
Julie Ann Sosa, Rossella Elisei, Barbara Jarząb, Jai Balkissoon, S. Lu, Chandrasekhar Bal, Shanthi Marur, Ann W. Gramza, R. Ben Yosef, Barbara J. Gitlitz, Bryan R. Haugen, Frank G. Ondrey, Charles Lu, S. M. Karandikar, Fadlo R. Khuri, Lisa Licitra, Scot C. Remick
Abstract
Although the study did not meet statistical significance in improvement in OS with the addition of fosbretabulin to carboplatin/paclitaxel, it represents the largest prospective randomized trial ever conducted in ATC. The regimen is well tolerated, with AEs and deaths primarily related to ATC and disease progression.
Related Papers
- → Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer(2016)360 cited
- → Cell-cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy(2007)28 cited
- Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel.(1996)
- → Weekly Carboplatin and Paclitaxel for Ovarian Cancer: The “Finer Points”(2020)4 cited
- Pharmacokinetics of paclitaxel and carboplatin in combination.(1995)